ProPharma Group Announces the Acquisition of The Weinberg Group
Overland Park, KS — ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Washington D.C.-based The Weinberg Group Inc. The Weinberg Group is a leading...
The Weinberg Group (now ProPharma Group) Adds Experts to Team
WASHINGTON, DC – OCTOBER 3, 2018 – The Weinberg Group (now ProPharma Group), is growing. In addition to people, the company has also expanded its capabilities. Building upon its role as the most...
The Weinberg Group CEO to Speak at AIPPI’s International Convention on the Economy of Innovation
WASHINGTON, DC – April 17, 2018 – Matthew Weinberg, Chief Executive Officer of The Weinberg Group Inc., will be speaking at the International Association for the Protection of Intellectual Property’s...
The Weinberg Group Donates to 21 Charities in Celebration of Giving Tuesday
WASHINGTON, DC – November 30, 2017 – The Weinberg Group Inc., a Washington, DC, based FDA consulting firm, today released a list of 21 charitable organizations that the firm contributed to on...
With Help of DC-Based FDA Consulting Firm, Baltimore Nonprofit Helps Minority Students Achieve Careers in STEM Fields
WASHINGTON, DC – July 26, 2017 – Building STEPS, a Baltimore-based nonprofit that helps minority and underprivileged high school students pursue careers in the fields of science and technology, was...
We Are Growing...
The Weinberg Group, the leading FDA consultancy, is excited to announce the addition of Paul Eichholz to our leadership team. As Senior Vice President, Quality and Compliance, with oversight of all...
Steve Jensen Joins The Weinberg Group (now ProPharma Group)
The Weinberg Group (now ProPharma Group), the leading FDA consulting firm, is pleased to announce that Steve Jensen has joined us as Senior Vice President, Head of Regulatory Consulting. Steve has...
Matthew Weinberg Quoted in Article about EMA’s Initiative to Broaden Expert Involvement with Updated Policy on Conflicts of Interest
FDANews Drug Industry Daily Nov. 21, 2014 Europe’s drug regulatory agency has revised the conflict of interest policy for its scientific committee members and experts, a move that one attorney says...
Matthew Weinberg Writes for Tobacco Reporter
CEO Matthew Weinberg writes for Tobacco Reporter Magazine encouraging stakeholders to take advantage of the opportunity to respond to FDA e-cigarette regulations.
Drug Companies Face Stricter Clinical Trial Regulation Worldwide
For more information on The Weinberg Group’s independent clinical auditing services, please contact Jeff Antos at jeff.antos@weinberggroup.com or 202.280.0815.